616 results on '"DEL-BEL, Elaine"'
Search Results
2. Cannabidiol exerts antipyretic effects by downmodulating inflammatory mediators in LPS-induced fever
3. Anti-nociceptive effects of non-antibiotic derivatives of demeclocycline and doxycycline against formalin-induced pain stimulation
4. Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission
5. Novel Proline Transporter Inhibitor (LQFM215) Presents Antipsychotic Effect in Ketamine Model of Schizophrenia
6. Doxycycline inhibits dopaminergic neurodegeneration through upregulation of axonal and synaptic proteins
7. 4′-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms
8. Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors
9. The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex
10. Doxycycline diminishes the rewarding and psychomotor effects induced by morphine and cocaine
11. Effects of hydrogen gas inhalation on L-DOPA-induced dyskinesia
12. Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
13. Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia
14. What Can We Learn from Animal Models to Study Schizophrenia?
15. Addressing the opportunity gap in the Latin American neuroscience community
16. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
17. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia
18. Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors
19. Experimental Periodontitis Worsens Dopaminergic Neuronal Degeneration.
20. Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556
21. Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson’s Disease: Focus on Neuroinflammation
22. Levodopa-induced dyskinesias in Parkinson’s disease increase cerebrospinal fluid nitric oxide metabolites’ levels
23. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum
24. Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats
25. The antibiotic doxycycline mimics the NGF signaling in PC12 cells: A relevant mechanism for neuroprotection
26. Doxycycline inhibits α-synuclein-associated pathologies in vitro and in vivo
27. In-tube solid-phase microextraction directly coupled to tandem mass spectrometry for anandamide and 2-arachidonoylglycerol determination in rat brain samples from an animal model of Parkinson's disease
28. Astrocyte Intracellular Ca2+and TrkB Signaling in the Hippocampus Could Be Involved in the Beneficial Behavioral Effects of Antidepressant Treatment
29. Cannabidiol improves non-motor symptoms, attenuates neuroinflammation, and favours hippocampal newborn neuronal maturation in a rat model of Parkinsonism.
30. Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease
31. Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors
32. Sodium nitroprusside enhances stepping test performance and increases medium spiny neurons responsiveness to cortical inputs in a rat model of Levodopa‐induced dyskinesias
33. Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia
34. Doxycycline Therapeutic Approach in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
35. Novel Pharmacotherapies for L-DOPA-Induced Dyskinesia
36. The two synthetic cannabinoid compounds 4′‐F‐CBD and HU‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes
37. The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex
38. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
39. Differential behavioral and glial responses induced by dopaminergic mechanisms in the iNOS knockout mice
40. The role of striatum and prefrontal cortex in the prevention of amphetamine-induced schizophrenia-like effects mediated by nitric oxide compounds
41. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases
42. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity
43. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia
44. Suppressing nNOS Enzyme by Small-Interfering RNAs Protects SH-SY5Y Cells and Nigral Dopaminergic Neurons from 6-OHDA Injury
45. The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases
46. Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity
47. Extrapyramidal Side Effects with Chronic Atypical Antipsychotic Can Be Predicted by Labeling Pattern of FosB and phosphoThr34-DARPP-32 in Nucleus Accumbens
48. Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides
49. Fish oil prevents rodent anxious states comorbid with diabetes: A putative involvement of nitric oxide modulation
50. CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.